[go: up one dir, main page]

Takara et al., 2012 - Google Patents

Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells

Takara et al., 2012

Document ID
7335680065997704034
Author
Takara K
Fujita M
Minegaki T
Yamamoto K
Takahashi M
Yokoyama T
Okumura K
Publication year
Publication venue
European journal of pharmaceutical sciences

External Links

Snippet

AIM: Combination chemotherapy for treating cancer often is superior in clinical efficacy to monotherapy. The aim of this study was to investigate the schedule-dependent effect of 5- fluorouracil (5-FU) and platinum derivatives (cisplatin or oxaliplatin) in colorectal cancer …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay

Similar Documents

Publication Publication Date Title
Pilié et al. State-of-the-art strategies for targeting the DNA damage response in cancer
Pokhriyal et al. Chemotherapy resistance in advanced ovarian cancer patients
Casero Jr et al. Polyamine metabolism and cancer: treatments, challenges and opportunities
Damaskos et al. Triple-negative breast cancer: The progress of targeted therapies and future tendencies
Subhash et al. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells
Fojo et al. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?
Kim et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma
Gioulbasanis et al. The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer
Giovannetti et al. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
Amos et al. Triple‐Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
Naus et al. Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways
Perez-Gracia et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: outcomes by prior number of regimens
Kimbung et al. Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition
Safra et al. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer
Takara et al. Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells
Seeber et al. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
Theile et al. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy
Theile et al. Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma
Sone et al. Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort
Koumarianou et al. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression
Yang et al. Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis
Tippett et al. The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review
Creemers et al. Inhibition of human adrenocortical cancer cell growth by temozolomide in vitro and the role of the MGMT gene
Sanfrancesco et al. Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology
Ahn et al. Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells